Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus SUPPRELIN LA.
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin secretion, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing gonadal steroid production (testosterone and estrogen).
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
3.75 mg IM every 4 weeks or 11.25 mg IM every 12 weeks for advanced prostate cancer; 3.75 mg IM every month for endometriosis or uterine leiomyomas; 7.5 mg IM monthly for central precocious puberty.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
3-4 hours for subcutaneous injection; after depot injection, initial burst release followed by slow release with apparent half-life of approximately 3-4 weeks due to absorption rate-limited elimination.
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Primarily renal (metabolites), approximately 5% unchanged; fecal elimination accounts for <5%.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category D/X
Category C
GnRH Agonist
GnRH Agonist